Boston Scientific’s (NYSE:BSX) Lotus transcatheter aortic valve implantation system fared well in an early feasibility study in patients with severe symptomatic aortic stenosis who were to sick to undergo open-heart surgery.
The Lotus system, designed to minimize valve leakage post-implant, was implanted in 11 patients at 3 Australian sites, with 1 incident of major in-hospital adverse cardiovascular or cerebrovascular event, 1 stroke and no deaths in the Reprise 1 trial. No moderate or severe leakage was seen after the valve placement or at patient discharge from the hospital.
The Lotus device, which Boston Scientific acquired in the 2011 with the $450 million buyout of Sadra Medical, is designed to minimize valve leakage post-implantation, according to a press release.
"Perhaps the most impressive feature of the Lotus Valve System in this study was the ability to precisely position the valve on the first attempt, eliminating the need for repositioning, although this capability was available if needed," principal investigator Ian Meredith said in prepared remarks. "Another striking feature was that the valve operated early in the deployment process, providing us some comfort and time to consider the valve position, as well as the immediate and almost complete obliteration of aortic regurgitation even in patients who had moderately severe aortic regurgitation after balloon valvuloplasty. In this regard, I think the Lotus valve technology is somewhat unique."
The Reprise II trial, which will be used to support a bid for CE Mark, will include about 120 patients at 15 sites. Enrollment is expected to close in the 1st half of 2013, according to the release.
Sapien landed FDA clearance in November 2011 for treatments of patients too sick to undergo open-heart surgery. Medtronic’s CoreValve TAVI system won CE Mark approval in the European Union in March 2007, and is expected to hit the U.S. market in 2014.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.